| ²é¿´: 4013 | »Ø¸´: 5 | ||
D-lindaÒø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
IIGÏ޶ȵÄÒÉÎÊ
|
|
1¡¢ÔÚFDAµÄInactive Ingredient Search for Approved Drug ProductsÍøÕ¾Éϲéѯ¸¨ÁϵÄ×î´óÓÃÁ¿£¬ÔÚMAXIMUM POTENCYÏîϵÄÊý×ÖÈ磺0.01%£¬0.18MGµÈ£¬ÕâЩֱ½Ó´ú±í×Å×î´óµÄÓÃÁ¿Ã´£¿ 2¡¢ÎÒÔÚ¡¶Ò©Óø¨ÁÏÓ¦ÓÃÖ¸ÄÏ¡·£¨Ò¦¾²£¬ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2011£¨8£©£©ÊéÖп´µ½µÄ¸¨ÁÏ×î¸ßÓÃÁ¿È´ÓëFDAµÄÏ޶Ȳ»Í¬£¬ÈçôDZ½±ûõ¥£ºFDA-oral suspension-4%£»Ò©Óø¨ÁÏÓ¦ÓÃÖ¸ÄÏ-¿Ú·þ»ìÐü¼Á-20.00%¡£ÔõôÓÐÕâô´óµÄ²î¾à°¡£¿ÔÚÕâ¸öÍøÖ·Éϲéѯhttp://www.drugfuture.com/fda/II ... ASNumber=&UNII=Ò²ÊÇ20% ÆÚÅÎÃ÷°×È˵Ľâ´ð~~ [ Last edited by D-linda on 2011-11-11 at 14:57 ] |
» ²ÂÄãϲ»¶
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
ÔÓÖʶÔÕÕÆ·¼Û¸ñÈçºÎ½ç¶¨ºÍÕýȷʹÓ÷½·¨
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ119È˻ظ´
ÔÑÐÖÆ¼Á¡¢·ÂÖÆÒ©£ºÔÓÖʶÔÕÕÆ·ÔÚÒ©Æ·Éú²úÖеÄÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
ÔÑÐÖÆ¼Á¡¢·ÂÖÆÒ©£ºÔÓÖʶÔÕÕÆ·ÔÚÒ©Æ·Éú²úÖеÄÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´
±ê׼ƷÔÚÉú²ú¹ý³ÌÖеÄÖØÒªÐÔºÍÓ¦ÓÃʵÀý
ÒѾÓÐ0È˻ظ´
ßÁ¶ßËØÔÓÖÊ
ÒѾÓÐ0È˻ظ´
Ë«ÑÎËáÌæÂå¡🚀 ¸ß´¿Îȶ¨・ͼÆ×ÍêÕû ¿¹²¡¶¾Ò©Ñз¢Ò»²½µ½Î»
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¹ØÓÚµÚ¶þÅú±¨ÃûµÄÒÉÎÊ£¬Çó½â´ð
ÒѾÓÐ4È˻ظ´
¹ØÓڽṹÃô¸Ð·´Ó¦Óë½á¹¹·ÇÃô¸Ð·´Ó¦µÄÒÉÎÊ
ÒѾÓÐ9È˻ظ´
¡¾Ã÷ÌìÈ¥²Î¼Ó¹«ÅÉ ¹¥¶Á²©Ê¿Ñ§Î»´ðÒɻᣬÓÐÒÉÎʵÄͬѧÇëÁôÑÔ£¬ÎÒ°ïÄãÃÇѯÎÊ¡¿
ÒѾÓÐ36È˻ظ´
µÚÒ»×÷ÕߺÍͨѶ×÷ÕßµÄÒÉÎÊ
ÒѾÓÐ16È˻ظ´
¹ØÓÚ¸Õ¸Õ½áÊøµÄ¹þ¹¤´ó¿¼²©µÄÒ»µãÒÉÎÊ
ÒѾÓÐ11È˻ظ´
¹ØÓÚº¸½Ó£¬Ñ¹Á¦¼Ó¹¤£¬ÖýÔìÑ¡·½ÏòµÄÇóÖú ºÍ¿¼ÑÐÒÉÎÊ
ÒѾÓÐ25È˻ظ´
ÌÖÂÛ¶Ô±¾¿Æ211¡¢985µÄÏÞÖÆ£¬Ö÷ÌâÊÇ̽ÌÖÑ¡ÈË»úÖÆºÏÀíÐÔÎÊÌ⣬²»Àí½â²»ÒªÂÒ·¢ÆÀÂÛ
ÒѾÓÐ4È˻ظ´
Çë½Ì»ù½ðÉêÇëÊéÖÐÉæ¼°¡°¸ß¼¶Ö°³Æ¡±µÄ¡°Á½ÏîÏÞÖÆ¡±ÎÊÌ⣡
ÒѾÓÐ18È˻ظ´
²ÐÁôÈܼÁµÄÏÞ¶ÈÎÊÌâ
ÒѾÓÐ5È˻ظ´
¹ØÓں鱤µÄÒÉÎÊ
ÒѾÓÐ4È˻ظ´
ÇëÎÊÃæÉÏ»ù½ðµÄÄêÁäÏÞÖÆÎÊÌâ
ÒѾÓÐ17È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚ¼ÆËãNICS£¨ºË¶ÀÁ¢»¯Ñ§Î»ÒÆ£©µÄһЩÒÉÎÊA
ÒѾÓÐ3È˻ظ´
¡¾ÇóÖú¡¿Óйع̶¨Éè¼Æ±äÁ¿µÄÒ»¸öÒÉÎÊ
ÒѾÓÐ3È˻ظ´

µÎË®²Øº£
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 3160.3
- ºì»¨: 2
- Ìû×Ó: 316
- ÔÚÏß: 177.9Сʱ
- ³æºÅ: 516231
- ×¢²á: 2008-03-02
- רҵ: Ò©Îï·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
´ÓÍ·¿ªÊ¼(½ð±Ò+1): ¸Ðл²ÎÓë 2011-12-31 11:27:38
D-linda(½ð±Ò+15): ¡ï¡ï¡ïºÜÓаïÖú ¸ÐлӦÖú 2012-01-03 14:11:01
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
´ÓÍ·¿ªÊ¼(½ð±Ò+1): ¸Ðл²ÎÓë 2011-12-31 11:27:38
D-linda(½ð±Ò+15): ¡ï¡ï¡ïºÜÓаïÖú ¸ÐлӦÖú 2012-01-03 14:11:01
|
¿´¿´FDAÒ©Îï·Ç»îÐԳɷÖÊý¾Ý¿â¹ØÓÚ¡°MAXIMUM POTENCY¡±µÄ˵Ã÷Äã¾ÍÃ÷°×ÁË¡£ Inactive Ingredient Field Descriptions Inactive Ingredient An inactive ingredient is any component of a drug product other than the active ingredient. Only inactive ingredients in the final dosage forms of drug products are included in this database. Route A route of administration is a way of administering a drug to a site in a patient. A comprehensive list of specific routes of administration appears in the Data Standards Manual. Dosage Form A dosage form is a form in which a drug is produced and dispensed. A comprehensive list of specific routes of administration appears in the Data Standards Manual. CAS Number The acronym "CAS" stands for "Chemical Abstracts Service," a division of the American Chemical Society that provides comprehensive electronic chemical information services. CAS assigns unique CAS Registry Numbers to chemical substances. Many inactive ingredients have CAS Registry Numbers, which are useful in searching other databases for chemical information. The CAS Registry Number itself has no chemical significance. Maximum Potency The "maximum potency" field specifies the maximum amount of inactive ingredient for each route/dosage form containing that ingredient. ÓÉ´Ë¿ÉÒÔ¿´³öÕâÊÇÿ¸ö¸øÒ©Í¾¾¶µÄµ¥¼ÁÁ¿Ëùº¬µÄ·Ç»îÐԳɷ֡£ When there is no calculable potency measurement for the inactive ingredient, the "maximum potency" field will be blank. UNII The acronym ¡°UNII¡± stands for ¡°Unique Ingredient Identifier¡± The UNII is a part of the joint USP/FDA Substance Registration System (SRS), which has been designed to support health information technology initiatives by providing unique identifiers for substances in drugs, biologics, foods, and devices based on molecular structure and/or descriptive information. The SRS is used to generate permanent, unique, unambiguous identifiers for substances in regulated products, such as ingredients in drug products. More information about the UNII and the SRS is available on the Data Council SRS page. All chemically-related questions about the UNII or the SRS that are not answered on the FDA website should be directed fda-srs@fda.hhs.gov. ´Ó¶¡ÏãÔ°¿´µ½µÄ£¬Ò²Ðí¶ÔÄãÓаïÖú |
2Â¥2011-12-31 10:43:42
µÎË®²Øº£
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 7 (Ó×¶ùÔ°)
- ½ð±Ò: 3160.3
- ºì»¨: 2
- Ìû×Ó: 316
- ÔÚÏß: 177.9Сʱ
- ³æºÅ: 516231
- ×¢²á: 2008-03-02
- רҵ: Ò©Îï·ÖÎö
¡ï
zhychen2008(½ð±Ò+1): ¶àл²ÎÓë 2011-12-31 11:33:36
zhychen2008(½ð±Ò+1): ¶àл²ÎÓë 2011-12-31 11:33:36
| Ó¦¸ÃÊǶÔ×î´ó¼ÁÁ¿µÄÀí½â»òÕß¼ÆË㲻ͬÔì³ÉµÄ²»Í¬£¨ÊÇÿµ¥Î»¡¢»¹ÊÇÿ´Î¡¢»¹ÊÇÿÈÕÓÃÁ¿µÄÏÞ¶È£¿£© |
3Â¥2011-12-31 10:46:29
D-linda
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 334.1
- ºì»¨: 1
- Ìû×Ó: 109
- ÔÚÏß: 48.2Сʱ
- ³æºÅ: 495714
- ×¢²á: 2008-01-15
- ÐÔ±ð: MM
- רҵ: Ò©Îï·ÖÎö
|
¸ÐлµÎË®²Øº£µÄ½â´ð¡£ ÔÚ¡¶Ò©Óø¨ÁÏÓ¦ÓÃÖ¸ÄÏ¡·ºÍdrugfutureÍøÕ¾ÉϵÄÊý¾Ý¾ù±íÃ÷À´Ô´ÓÚFDA£¬µ«È´Î´ËµÃ÷×ÔÉí¶ÔIIGµÄ¶¨Òå·¢Éú¸Ä±ä¡£ È磺 ¡¾drugfutureÊý¾Ý¿â˵Ã÷£º 1¡¢±¾Êý¾Ý¿âΪFDAÅú×¼Ò©ÎïËùʹÓõķǻîÐԳɷÖÊý¾Ý¿â£¬¼´FDAÉÏÊвúÆ·Öаüº¬µÄ¸¨ÁÏÐÅÏ¢Êý¾Ý¡£ 2¡¢¼ìË÷Ìõ¼þÖ§³ÖÄ£ºý²éѯ£¬¸÷ÊäÈëÌõ¼þ¼äµÄ¼ìË÷¹ØÏµÎªÂß¼Ó루¼´AND¹ØÏµ£©¡£ 3¡¢¼ìË÷½á¹û°üÀ¨£º·Ç»îÐԳɷÖÃû³Æ¡¢¸øÒ©Í¾¾¶»ò¼ÁÐÍ¡¢CASµÇ¼ÇºÅ¡¢ÃÀ¹úÒ©µä/FDAÎïÖʵǼÇϵͳΨһ±êʶÂë¡¢´¦·½Öи¨ÁÏʹÓÃÁ¿¡£ 4¡¢ÀûÓñ¾Êý¾Ý¿â¿ÉÒÔΪҩÎïÑо¿¿ª·¢ÕßÌṩ¸¨ÁϵݲȫÓÃÁ¿µÄÊÂʵÐÔÊý¾Ý¡£ 5¡¢Êý¾Ý¸üÐÂÓëFDAͬ²½£¬µ±Ç°Êý¾ÝÁ¿:11066Ìõ£¬×îºó¸üÐÂÈÕÆÚ£º2011/9/3¡£¡¿ Ö»ÓÐÕâЩÐÅÏ¢ Ŀǰ´òËãÒÔFDA¹ÙÍøµÄÊý¾ÝΪ׼£¬µ«ÊÇÕâ¸öÎÊÌ⻹ÊÇû¸ãÇå³þ¡£ Ò²¿ÉÄÜÊǸüÐÂʱ¼ä²»Ò»Ö£¬FDAµÄÊý¾Ý¸üУ¬ÖÐÎÄÍøÕ¾Ã»¸úÉÏ£¬²»¹ý¸Ð¾õ¿ÉÄÜÐÔ²»´ó£¬ÒòΪÊý¾Ý²»Ò»Öµĵط½»¹Í¦¶à¡£ FDA:Update Frequency: Quarterly Data Through: October 12, 2011 Database Last Updated: October 14, 2011 |

4Â¥2012-01-03 14:09:02
sam1223321108
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1.9
- Ìû×Ó: 137
- ÔÚÏß: 79.3Сʱ
- ³æºÅ: 411965
- ×¢²á: 2007-06-24
- ÐÔ±ð: MM
- רҵ: Ò©¼Áѧ
|
ÔÚÊý¾Ý¿âÖа´ÕÕ¼ÁÐÍ¡¢ÓÃҩ;¾¶²éÕÒ£ºÀýÈçLOZENGE£¬½øÈëÏÂÃæµÄ¸¨ÁÏÔÚLOZENGEÖÐÓÐÊý¾Ý¡£ Èç¹ûÒª²éÕÒÆäËû³É·ÖµÄ£¬ÀýÈç¡°ÆÏÌÑÌÇ¡±µÈ³£Óã¬Ó¦²ÎÕÕÄÇÖÖ¼ÁÐÍ£¿ ÐòºÅ ·Ç»îÐԳɷÖÃû³Æ ¸øÒ©Í¾¾¶»ò¼ÁÐÍ CASµÇ¼ÇºÅ Ψһ±êʶÂë ×î´óÓÃÁ¿ µ¥Î» ¸¨ÁÏÊý¾Ý 1 BUFFERED SODA SUBLINGUAL; TABLET, UNCOATED, LOZENGE N/A 40 MG 2 CITRIC ACID ORAL; TABLET, UNCOATED, LOZENGE 5949291 2968PHW8QP 9.8 MG 3 CROSCARMELLOSE SODIUM SUBLINGUAL; TABLET, UNCOATED, LOZENGE 74811657 M28OL1HH48 10 MG 4 DEXTRATES ORAL; TABLET, UNCOATED, LOZENGE G263MI44RU 598.8 MG 5 FERRIC OXIDE YELLOW SUBLINGUAL; TABLET, UNCOATED, LOZENGE 51274001 EX438O2MRT 1 MG 6 IRON OXIDE BEIGE SUBLINGUAL; TABLET, UNCOATED, LOZENGE N/A 2 MG 7 MAGNESIUM STEARATE ORAL; TABLET, UNCOATED, LOZENGE 557040 70097M6I30 15 MG 8 PHARMABURST B2 SUBLINGUAL; TABLET, UNCOATED, LOZENGE N/A 132.75 MG 9 SILICON DIOXIDE SUBLINGUAL; TABLET, UNCOATED, LOZENGE 7631869 ETJ7Z6XBU4 8 MG 10 SILICON DIOXIDE, COLLOIDAL SUBLINGUAL; TABLET, UNCOATED, LOZENGE 7631869 ETJ7Z6XBU4 2 MG 11 SODIUM PHOSPHATE, DIBASIC, ANHYDROUS ORAL; TABLET, UNCOATED, LOZENGE 7558794 22ADO53M6F 31 MG 12 SODIUM STEARYL FUMARATE SUBLINGUAL; TABLET, UNCOATED, LOZENGE 4070808 7CV7WJK4UI 10 MG 13 STARCH, PREGELATINIZED ORAL; TABLET, UNCOATED, LOZENGE N/A 80 MG 14 SUCRALOSE SUBLINGUAL; TABLET, UNCOATED, LOZENGE 56038132 96K6UQ3ZD4 1.5 MG 15 SUGAR CONFECTIONERS ORAL; TABLET, UNCOATED, LOZENGE 57501 C151H8M554 1255 MG |
5Â¥2015-01-23 13:37:28
xueemma
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 4202.4
- É¢½ð: 31
- ºì»¨: 4
- Ìû×Ó: 593
- ÔÚÏß: 187.6Сʱ
- ³æºÅ: 1058461
- ×¢²á: 2010-07-15
- ÐÔ±ð: MM
- רҵ: Ò©¼Áѧ
6Â¥2015-12-14 09:47:57













»Ø¸´´ËÂ¥
5